| Literature DB >> 30126154 |
Patrycja Kapczuk1, Danuta Kosik-Bogacka2, Natalia Łanocha-Arendarczyk3, Izabela Gutowska4, Patrycja Kupnicka5, Dariusz Chlubek6, Irena Baranowska-Bosiacka7.
Abstract
The rat tapeworm Hymenolepis diminuta is a parasite of the small intestine of rodents (mainly mice and rats), and accidentally humans. It is classified as a non-invasive tapeworm due to the lack of hooks on the tapeworm's scolex, which could cause mechanical damage to host tissues. However, many studies have shown that metabolites secreted by H. diminuta interfere with the functioning of the host's gastrointestinal tract, causing an increase in salivary secretion, suppression of gastric acid secretion, and an increase in the trypsin activity in the duodenum chyme. Our work presents the biochemical and molecular mechanisms of a parasite-host interaction, including the influence on ion transport and host intestinal microflora, morphology and biochemical parameters of blood, secretion of antioxidant enzymes, expression of Toll-like receptors, mechanisms of immune response, as well as the expression and activity of cyclooxygenases. We emphasize the interrelations between the parasite and the host at the cellular level resulting from the direct impact of the parasite as well as host defense reactions that lead to changes in the host's tissues and organs.Entities:
Keywords: hymenolepidosis; molecular mechanisms; parasite–host system; rat
Mesh:
Year: 2018 PMID: 30126154 PMCID: PMC6121280 DOI: 10.3390/ijms19082435
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Biochemical and molecular mechanisms of Hymenolepis diminuta’s effect on the host organism. 1. The parasite affects changes in the metabolism of acetylcholine, which stimulates the action of muscarinic receptors by changing their conformation. The muscarinic receptors can modulate the contraction by binding to the G protein. Activation of phospholipase C (PLC) by the G protein results in the formation of the inositol triphosphate signal molecule (IP3) and thus an increase in Ca2+ concentration in the cytoplasm. Ca2+ ions initiate a contraction, and an increase in their concentration is associated with the greater strength of contraction; 2. Hymenolepidosis causes an increase in the activity and expression of COX-1 and COX-2 that produce TX and PG; 3. H. diminuta in the host’s body may cause oxidative stress manifested by an increase in lipid peroxidation and their products, such as MDA (malondialdehyde dialdehyde), and changes in antioxidant enzyme activity in various parts of the gastrointestinal tract: in the duodenum, a decrease in GPx activity and increase in GR activity; in the intestine an increase in GR, GSH, CAT, and GPx activity and a decrease in SOD activity; 4. The excretory-secretory products (ESP) of the parasite inhibit pro-inflammatory cytokines and chemokines, reducing the expression of transcription factors (NFκB, p65, IRF3) and the CD36 scavenger receptor; 5. H. diminuta infection causes a reduced absorption of electrolytes and glucose in the small intestine of the host; 6. By secretion of cGMP, which connects to the mucous membrane of the host intestine via the cGMP receptor, H. diminuta can affect intestinal peristalsis; 7. In the course of hymenolepidosis, the host organism produces inflammation mediators, including mast cells. The histamine-secreted mastocytes stimulate the nervous system C-fibers that lead to the release of non-noradrenergic non-adrenaline (NANC) neuropeptides, including P (SP), neurokinin A (NKA), and calcitonin-related peptides (CGRP). This phenomenon may lead to neurogenic inflammation and may cause a reduction of transepithelial electrical potential, reducing ion transport; e.g., Na+ and Cl−; 8. The parasite reduces villus length and deepens the crypts in the host’s digestive tract; 9. H. diminuta causes disturbances in hematological blood values and changes in the composition of plasma: an increase in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) and alkaline phosphatase (ALP), a decrease in biochemical parameters, including total protein (TP), albumin (ALB) and globulins (GLOB). Hymenolepidosis causes a reduction in the number of red blood cells (RBC), hemoglobin (HGB), red cell distribution width (RDW), and an increase in mean red cell volume (MCV). In the white blood cell system (WBC) there is a decrease in the number of cases or an increase in the number of eosinophils (EOS) that release the main alkaline protein (MBP) and eosinophil cationic protein (ECP). In the lymphocytic system, the activation of B lymphocytes responsible for the production of IgA class secreting antibodies (S-IgA) and IgE occur. In addition, B lymphocytes from H. diminuta–infected rats reduce the effects of dinitrobenzene sulfonic acid (DNBS), favoring the suppression of colitis and an increase in the production of interleukins (IL-4 and IL-10); 10. Hymenolepidosis causes changes in the composition of the bacterial microbiota in the gut of the host in the form of reducing the percentage of Bacillus spp. in relation to Clostridium spp. 11 H. diminuta infection affects the growth of Toll-like receptor (TLR) expression, including TLR2, TLR3, TLR4 and TLR9 in the host’s digestive tract.
Figure 2Signaling pathways for TLR2, TLR3, TLR4, and TLR9. Signaling pathways derived from TLRs are very complex. Two major pathways are suggested: MYD88 (myeloid differentiation primary response gene 88) and TRIF (TIR-domain containing adapter inducing IFN-ß). MYD88-dependent signaling pathways are derived from TLR2, TLR4, and TLR9, whereas TLR3 uses TRIF protein for transduction. To activate MYD88, TLR4 uses TIRAP (TIR-domain containing adapter protein) and TRAM (TRIF-related adapter molecule), while TLR uses TIRAP only. As a result of MYD88–dependent signaling pathways, transcription factors are activated: AP-1 (activator protein 1) and NFκB (nuclear factor kappa-light-chain-enhancer of activated B cells), while transcription factors within the MYD88–independent pathways activate IRF (IFN regulators factor) 3 and 7 and NFκB. TLR4 is a receptor that has signal transduction capabilities in both these pathways [138,139].